An FDA advisory committee may have ruled in elamipretide’s favor back in October, but it looks like Stealth BioTherapeutics ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 2 ...

THE LAWSUIT: A class action securities lawsuit was filed against Applied Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American ...

Malawi breaking news publishing 24 hours a day news about Malawi, Malawi Business, Malawi Tourism, Malawi Politics, Malawi News ...

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney ...

The grant money will be used to create new degree programs at Reynolds and Brightpoint community colleges to help develop the ...

As AI is integrated into health care, clinicians can acknowledge the technology’s limitations and help shape its future in medicine, according to experts.Healio, in partnership with LinkedIn News, ...

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.